BioWorld

Aug. 2, 2007

Hana Licenses Zensana To Par, Focuses On Oncology Pipeline

Hana Biosciences Inc., which earlier this year withdrew a new drug application filing for the antiemetic agent Zensana, licensed the product to Par Pharmaceutical Cos. Inc. (BioWorld Today) Read More

Advisory Panel: Thumbs Up To Tysabri For Limited Use In CD

Better Magnetic Nanoparticle May Enable Virus-Free Gene Therapy

Diagnostic Lab Firm Genoptix Files for $86.25 Million IPO

Clinic Roundup

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Feb. 11, 2025.

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

Astellas’ ASP-2246 shows promise in stroke management

BioWorld Science

Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...

News in brief

BioWorld Asia

BioWorld Asia briefs for Feb. 10, 2026

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...